9 Sources of evidence considered by the Committee

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the NHS Centre for Reviews and Dissemination and Centre for Health Economics, University of York:

  • Fayter D, Spackman E, Epstein D et al., Teriflunomide for treating relapsing forms of multiple sclerosis, July 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were also invited to comment on the draft scope, the ERG report and the appraisal consultation document. Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Genzyme

II. Professional/specialist and patient/carer groups:

  • Association of British Neurologists

  • Multiple Sclerosis Society

  • Multiple Sclerosis Trust

  • Primary Care Neurology Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

  • United Kingdom Multiple Sclerosis Specialist Nurse Association

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Biogen

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on teriflunomide by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the appraisal consultation document.

  • Dr Waqar Rashid, Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, nominated by the Multiple Sclerosis Society - clinical specialist

  • Professor Neil Scolding, Consultant Neurologist, Bristol, nominated by the Association of British Neurologists - clinical specialist

  • Nick Rijke, Director of Policy and Research, the Multiple Sclerosis Society, nominated by the Multiple Sclerosis Society - patient expert

  • Joanne Thomson, nominated by the Multiple Sclerosis Trust - patient expert

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Genzyme

  • National Institute for Health and Care Excellence (NICE)